Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients

Br J Clin Pharmacol. 2022 Aug;88(8):3920-3921. doi: 10.1111/bcp.15321. Epub 2022 Mar 29.

Authors

Simon E Koele¹, Stijn W van Beek¹, Anthonie J van der Wekken², Berber Piet³, Michel M van den Heuvel³, Rob Ter Heine¹

Affiliations

¹ Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
² Department of Pulmonary Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
³ Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands.

PMID: 35350084
DOI: 10.1111/bcp.15321

No abstract available

Keywords: chemotherapy; pharmacokinetics; therapeutic drug monitoring.

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Organophosphorus Compounds
Protein Kinase Inhibitors / therapeutic use
Pyrimidines

Substances

Organophosphorus Compounds
Protein Kinase Inhibitors
Pyrimidines
brigatinib